We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×

Sugar ligand-mediated drug delivery

    Fang Chen

    Chongqing Key Laboratory of Green Synthesis & Application, Active Carbohydrate Research Institute, Chongqing Normal University, Chongqing 401331, China

    ,
    Gangliang Huang

    *Author for correspondence:

    E-mail Address: huangdoctor226@163.com

    Chongqing Key Laboratory of Green Synthesis & Application, Active Carbohydrate Research Institute, Chongqing Normal University, Chongqing 401331, China

    &
    Hualiang Huang

    School of Chemistry & Environmental Engineering, Wuhan Institute of Technology, Wuhan 430073, China

    Published Online:https://doi.org/10.4155/fmc-2019-0114

    Sugar ligand molecules, such as mannose, galactose and glucose, can bind to drug-delivery systems, making them targeted. These glycosylation ligands have the advantages of nontoxicity, no immunogenicity, good biocompatibility and biodegradation. They can be widely used in glycosylation-modified drug-delivery systems. Herein, the targeting mechanisms, synthesis methods and targeting characteristics of glycosylation-modified drug-delivery systems were reviewed.

    Papers of special note have been highlighted as: •• of considerable interest

    References

    • 1. Huang G, Mei X. Synthetic glycosylated natural products have satisfactory activities. Curr. Drug Targets 15(8), 780–784 (2014). •• The synthesized glycosylated natural products have good activities.
    • 2. Gao H, Huang G. Synthesis, anticancer activity and cytotoxicity of galactosylated epothilone B. Bioorg. Med. Chem. 26(20), 5578–5581 (2018). •• Galactosylated epothilone B has good anticancer activity and low cytotoxicity.
    • 3. Dodson AT. Acrylamide is formed in the Maillard reaction. Nature 419(6906), 448–449 (2002).
    • 4. Baranwal A, Mukherjee J. 18F-Fluorodeoxyglucamines: reductive amination of hydrophilic 18F-fluoro-2-deoxyglucose with lipophilic amines for the development of potential PET imaging agents. Bioorg. Med. Chem. Lett. 25(15), 2902–2906 (2015).
    • 5. Huang G, Gao H, Yi C et al. Preparation and antiproliferative activity of glucose – acetylsalicylic acid conjugate. Pharm. Chem. J. 51(2), 111–114 (2017).
    • 6. Jian W, He J, Sun Y et al. Comparative studies on physicochemical properties of bovine serum albumin-glucose and bovine serum albumin-mannose conjugates formed via Maillard reaction. LWT - Food Sci. Technol. 69, 358–364 (2016).
    • 7. Li J, Ma F, Dang Q et al. Glucose-conjugated chitosan nanoparticles for targeted drug delivery and their specific interaction with tumor cells. Front. Mater. Sci. 8(4), 363–372 (2014).
    • 8. Moretton MA, Bernabeu E, Grotz E et al. A glucose-targeted mixed micellar formulation outperforms Genexol in breast cancer cells. Eur. J. Pharm. Biopharm. 114, 305–316 (2017).
    • 9. Liu R, Li H, Gao X et al. Mannose-conjugated platinum complexes reveals effective tumor targeting mediated by glucose transporter 1. Biochem. Biophys. Res. Commun. 487(1), 34–40 (2017).
    • 10. Zhang X, Huang G. Synthetic lipoprotein as nano-material vehicle in the targeted drug delivery. Drug Deliv. 24(2), 16–21 (2017). •• Synthetic lipoprotein as nanomaterial vehicle was used in the targeted drug delivery.
    • 11. Byeon HJ, Thao Q, Lee S et al. Doxorubicin-loaded nanoparticles consisted of cationic- and mannose-modified-albumins for dual-targeting in brain tumors. J. Control. Rel. 225, 301–313 (2016).
    • 12. Chaubey P, Mishra B. Mannose-conjugated chitosan nanoparticles loaded with rifampicin for the treatment of visceral leishmaniasis. Carbohydr. Polym. 101(1), 1101–1108 (2014).
    • 13. Li L, Zhang R, Gu W et al. Mannose-conjugated layered double hydroxide nanocomposite for targeted siRNA delivery to enhanced cancer therapy. Nanomed. Nanotechnol. Biol. Med. 14(7), 2355–2364 (2017).
    • 14. Sharma R, Mody N, Kushwah V et al. C-Type lectin receptor(s)-targeted nanoliposomes: an intelligent approach for effective cancer immunotherapy. Nanomedicine 12(16), 1945–1959 (2017).
    • 15. Kim H, Kim BH, Huh BK et al. Surgical suture releasing macrophage-targeted drug-loaded nanoparticles for an enhanced anti-inflammatory effect. Biomater. Sci. 5(8), 1670–1677 (2017).
    • 16. Wu M, Li H, Liu R et al. Galactose conjugated platinum(II) complex targeting the Warburg effect for treatment of non-small cell lung cancer and colon cancer. Eur. J. Med. Chem. 110(167), 32–42 (2016).
    • 17. Jain A, Kesharwani P, Garg NK et al. Galactose engineered solid lipid nanoparticles for targeted delivery of doxorubicin. Colloid Surface B 134, 47–58 (2015).
    • 18. Liu JL, Li Q, Xing XJ et al. Characteristic fluorescence of bovine serum albumin and different sugar Maillard reaction systems. J. Food Safety Qual. 2015(5), 1819–1827 (2015).
    • 19. Jain K, Kesharwani P, Gupta U et al. A review of glycosylated carriers for drug delivery. Biomaterials 33(16), 4166–4186 (2012).
    • 20. Ulbrich K, Knobloch T, Kreuter J. Targeting the insulin receptor: nanoparticles for drug delivery across the blood–brain barrier (BBB). J. Drug Target. 19(2), 125–132 (2010).
    • 21. Qu B, Li X, Guan M et al. Design, synthesis and biological evaluation of multivalent glucosides with high affinity as ligands for brain targeting liposomes. Eur. J. Med. Chem. 72, 110–118 (2014).
    • 22. Buchanan MK, Needham CN, Neill NE et al. Glycoconjugated site-selective DNA-methylating agent targeting glucose transporters on glioma cells. Biochemistry 56(2), 421–440 (2017).
    • 23. Wang YC, Liu XQ, Sun TM et al. Functionalized micelles from block copolymer of polyphosphoester and poly(epsilon-caprolactone) for receptor-mediated drug delivery. J. Control. Rel. 128(1), 32–40 (2008).
    • 24. Xu B, Wang N, Pan W et al. Synthesis and anti-tumor activity evaluation of Matijin-Su derivatives. Bioorg. Chem. 56, 34–40 (2014).
    • 25. Zou Y, Song Y, Yang W et al. Galactose-installed photo-crosslinked pH-sensitive degradable micelles for active targeting chemotherapy of hepatocellular carcinoma in mice. J. Control. Rel. 193, 154–161 (2014).
    • 26. Zhang X, Huang G, Huang H. The glyconanoparticle as carrier for drug delivery. Drug Deliv. 25(1), 1840–1845 (2018). •• Glyconanoparticle as a carrier for drug delivery was summarized.
    • 27. Huang G, Huang H. Application of hyaluronic acid as carriers in drug delivery. Drug Deliv. 25(1), 766–772 (2018). •• Hyaluronic acid as a carrier was applied in drug delivery.
    • 28. Huang G, Liu Y, Chen L. Chitosan and its derivatives as vehicles for drug delivery. Drug Deliv. 24(2), 108–113 (2017). •• Chitosan and its derivatives as vehicles for drug delivery were summarized.
    • 29. Zhu L, Chen L, Cao QR et al. Preparation and evaluation of mannose receptor mediated macrophage targeting delivery system. J. Control. Rel. 152(Suppl. 1), e190–e191 (2011).
    • 30. Stockert RJ, Morell AG. Hepatic binding protein: the galactose-specific receptor of mammalian hepatocytes. Hepatology 3(5), 750–757 (2010).
    • 31. Huang S, Huang G. Synthesis, anticancer activity and cytotoxicity of 7-O-β-D-galactosyl-polyethylene glycol-epothilone B. Chem. Biol. Drug Des. 93(4), 539–543 (2019).
    • 32. Cheng H, Huang H, Huang G. Synthesis and antitumor activity of epothilone B. Eur. J. Med. Chem. 157, 925–934 (2018). •• Epothilone B is a promising compound.
    • 33. Huang S, Huang G. Preparation and drug delivery of dextran-drug complex. Drug Deliv. 26(1), 252–261 (2019). •• The dextran–drug complex was used for drug delivery.
    • 34. Chu S, Tang C, Yin C. Effects of mannose density on in vitro and in vivo cellular uptake and RNAi efficiency of polymeric nanoparticles. Biomaterials 52, 229–239 (2015).
    • 35. Štimac A, Cvitaš JT, Frkanec L et al. Design and syntheses of mono and multivalent mannosyl-lipoconjugates for targeted liposomal drug delivery. Int. J. Pharmaceut. 511(1), 44–56 (2016).
    • 36. Ye Z, Zhang Q, Wang S et al. Tumour-targeted drug delivery with mannose-functionalized nanoparticles self-assembled from amphiphilic β-cyclodextrins. Chem. Eur. J. 22(43), 15216–15221 (2016).
    • 37. Liu R, Fu Z, Zhao M et al. GLUT1-mediated selective tumor targeting with fluorine containing platinum(II) glycoconjugates. Oncotarget 8(24), 39476–39496 (2017).
    • 38. Zhang Q, Cai Y, Li QY et al. Targeted delivery of a mannose-conjugated BODIPY photosensitizer by nanomicelles for photodynamic breast cancer therapy. Chem. Eur. J. 23(57), 14307–14315 (2017).
    • 39. He QL, Minn I, Wang Q et al. Targeted delivery and sustained antitumor activity of triptolide through glucose conjugation. Angew. Chem. Int. Ed. Engl. 55(39), 12035–12039 (2016).
    • 40. Solá RJ, Griebenow K. Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy. BioDrugs 24(1), 9–21 (2010).
    • 41. Duelli R, Maurer MH, Staudt R et al. Increased cerebral glucose utilization and decreased glucose transporter Glut1 during chronic hyperglycemia in rat brain. Brain Res. 858(2), 338–347 (2000).
    • 42. Osorio F, Reise SC. Myeloid C-type lectin receptors in pathogen recognition and host defense. Immunity 34(5), 651–664 (2011).
    • 43. Bianucci AM, Chiellini F. A 3D model for the human hepatic asialoglycoprotein receptor (ASGP-R). J. Biomol. Struct. Dyn. 18(3), 435–451 (2000).
    • 44. Frederick JR, Petri WA Jr. Roles for the galactose-/N-acetylgalactosamine-binding lectin of entamoeba in parasite virulence and differentiation. Glycobiology 15(12), 53R–59R (2005).
    • 45. Irjala H, Alanen K, Grénman R et al. Mannose receptor (MR) and common lymphatic endothelial and vascular endothelial receptor (CLEVER)-1 direct the binding of cancer cells to the lymph vessel endothelium. Cancer Res. 63(15), 4671–4676 (2003).
    • 46. Pasieka TJ, Maresova L, Shiraki K et al. Regulation of varicella-zoster virus-induced cell-to-cell fusion by the endocytosis-competent glycoproteins gH and gE. J. Virol. 78(6), 2884–2896 (2004).
    • 47. Costa A, Sarmento B, Seabra V. Targeted drug delivery systems for lung macrophages. Curr. Drug Targets 16(14), 1565–1581 (2015).
    • 48. Pino RM. Ultrastructural localization of lectin receptors on the bone-marrow sinusoidal endothelium of the rat. Am. J. Anat. 169(3), 259–272 (1984).
    • 49. Nita-Lazar M, Banerjee A, Feng C et al. Desialylation of airway epithelial cells during influenza virus infection enhances pneumococcal adhesion via galectin binding. Mol. Immunol. 65(1), 1–16 (2015).
    • 50. He XW, Li WL, Li C et al. Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic stroke. Sci. Rep. 7, 40994 (2017).
    • 51. Thöle M, Nobmann S, Huwyler J et al. Uptake of cationized albumin coupled liposomes by cultured porcine brain microvessel endothelial cells and intact brain capillaries. J. Drug Target. 10(4), 337–344 (2002).
    • 52. Omidi Y, Barar J. Impacts of blood-brain barrier in drug delivery and targeting of brain tumors. Bioimpacts 2(1), 5–22 (2012).
    • 53. Huang G. Glyconanoparticles-an update. Curr. Med. Chem. 20(6), 782–788 (2013).